{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:37:43Z","timestamp":1792013863760,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04733-y","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:14:48Z","timestamp":1772280888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sinusoidal cell\u2013derived biomarker scores predict diagnosis and prognosis in chronic liver disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Sergi","family":"Guix\u00e9-Muntet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Fern\u00e1ndez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Tonina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiliam","family":"Fundora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zagorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gracia-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"4733_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/J.JHEP.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337. https:\/\/doi.org\/10.1016\/J.JHEP.2023.03.017.","journal-title":"J Hepatol"},{"key":"4733_CR2","doi-asserted-by":"publisher","unstructured":"Gibert-Ramos A, Andr\u00e9s-Rozas M, Past\u00f3 R, Alfaro-Retamero P, Guix\u00e9-Muntet S, Gracia-Sancho J. Sinusoidal communication in chronic liver disease. Clin Mol Hepatol. 2024. https:\/\/doi.org\/10.3350\/CMH.2024.0734.","DOI":"10.3350\/CMH.2024.0734"},{"key":"4733_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225719","volume":"13","author":"A Gibert-Ramos","year":"2021","unstructured":"Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Mart\u00ednez-Alcocer A, Gracia-Sancho J, Guix\u00e9-Muntet S, et al. The hepatic sinusoid in chronic liver disease: the optimal milieu for cancer. Cancers (Basel). 2021;13:5719. https:\/\/doi.org\/10.3390\/cancers13225719.","journal-title":"Cancers (Basel)"},{"key":"4733_CR4","doi-asserted-by":"publisher","unstructured":"Aizarani N, Saviano A, Sagar, Mailly L, Durand S, Herman JS, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. 2019;572:199\u2013204. https:\/\/doi.org\/10.1038\/s41586-019-1373-2.","DOI":"10.1038\/s41586-019-1373-2"},{"key":"4733_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06318-7","volume":"9","author":"SA MacParland","year":"2018","unstructured":"MacParland SA, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun. 2018;9:1\u201321. https:\/\/doi.org\/10.1038\/s41467-018-06318-7.","journal-title":"Nat Commun"},{"key":"4733_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575:512\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1631-3.","journal-title":"Nature"},{"key":"4733_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/J.MOLCEL.2017.01.023","volume":"65","author":"C Ziegenhain","year":"2017","unstructured":"Ziegenhain C, Vieth B, Parekh S, Reinius B, Guillaumet-Adkins A, Smets M, et al. Comparative analysis of single-cell RNA sequencing methods. Mol Cell. 2017;65:631-643.e4. https:\/\/doi.org\/10.1016\/J.MOLCEL.2017.01.023.","journal-title":"Mol Cell"},{"key":"4733_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155:1140\u201353. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.006.","journal-title":"Gastroenterology"},{"key":"4733_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VWS, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.027.","journal-title":"J Hepatol"},{"key":"4733_CR10","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/hep.31622\/suppinfo","volume":"73","author":"R Loomba","year":"2020","unstructured":"Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2020;73:2021. https:\/\/doi.org\/10.1002\/hep.31622\/suppinfo.","journal-title":"Hepatology"},{"key":"4733_CR11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","volume":"165","author":"G Semmler","year":"2023","unstructured":"Semmler G, Yang Z, Fritz L, K\u00f6ck F, Hofer BS, Balcar L, et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease. Gastroenterology. 2023;165:1041\u201352. https:\/\/doi.org\/10.1053\/j.gastro.2023.06.030.","journal-title":"Gastroenterology"},{"key":"4733_CR12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/HEP.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the Simtuzumab trials. Hepatology. 2019;70:1913\u201327. https:\/\/doi.org\/10.1002\/HEP.30664.","journal-title":"Hepatology"},{"key":"4733_CR13","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1111\/liv.14610","volume":"40","author":"G Pietrosi","year":"2020","unstructured":"Pietrosi G, Fern\u00e1ndez-Iglesias A, Pampalone M, Ortega-Ribera M, Lozano JJ, Garc\u00eda-Calder\u00f3 H, et al. Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats. Liver Int. 2020;40:2500\u201314. https:\/\/doi.org\/10.1111\/liv.14610.","journal-title":"Liver Int"},{"key":"4733_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/S41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382. https:\/\/doi.org\/10.1038\/S41587-019-0114-2.","journal-title":"Nat Biotechnol"},{"key":"4733_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/HEP.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73:625\u201343. https:\/\/doi.org\/10.1002\/HEP.31622.","journal-title":"Hepatology"},{"key":"4733_CR16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/HEP.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2022;75:1235\u201346. https:\/\/doi.org\/10.1002\/HEP.32204.","journal-title":"Hepatology"},{"key":"4733_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","volume":"9","author":"S Guix\u00e9-Muntet","year":"2024","unstructured":"Guix\u00e9-Muntet S, Quesada-V\u00e1zquez S, Gracia-Sancho J. Pathophysiology and therapeutic options for cirrhotic portal hypertension. Lancet Gastroenterol Hepatol. 2024;9:646\u201363. https:\/\/doi.org\/10.1016\/S2468-1253(23)00438-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4733_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/GUTJNL-2023-329923","volume":"73","author":"A Juanola","year":"2023","unstructured":"Juanola A, Ma AT, De Wit K, Gananandan K, Roux O, Zaccherini G, et al. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis. Gut. 2023;73:156\u201365. https:\/\/doi.org\/10.1136\/GUTJNL-2023-329923.","journal-title":"Gut"},{"key":"4733_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII \u2013 renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022.","journal-title":"J Hepatol"},{"key":"4733_CR20","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/S41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Shankar SS, Yates KP, Bolognese J, Daly E, Dehn CA, et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med. 2023;29:2656\u201364. https:\/\/doi.org\/10.1038\/S41591-023-02539-6.","journal-title":"Nat Med"},{"key":"4733_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101062","author":"M Pearson","year":"2024","unstructured":"Pearson M, Nobes J, Macpherson I, Gold L, Miller M, Dow E, et al. Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality. JHEP Rep. 2024. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101062.","journal-title":"JHEP Rep"},{"key":"4733_CR22","doi-asserted-by":"publisher","unstructured":"Anstee QM, Berentzen TL, Nitze LM, Jara M, Jensen AB, Kj\u00e6r MS, et al. Prognostic utility of Fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. The Lancet Regional Health - Europe. 2024;36. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100780.","DOI":"10.1016\/j.lanepe.2023.100780"},{"key":"4733_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/J.ADDR.2017.05.007","volume":"121","author":"T Higashi","year":"2017","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27\u201342. https:\/\/doi.org\/10.1016\/J.ADDR.2017.05.007.","journal-title":"Adv Drug Deliv Rev"},{"key":"4733_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","volume":"58","author":"G Marrone","year":"2013","unstructured":"Marrone G, Russo L, Rosado E, Hide D, Garc\u00eda-Carde\u00f1a G, Garc\u00eda-Pag\u00e1n JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 2013;58:98\u2013103. https:\/\/doi.org\/10.1016\/j.jhep.2012.08.026.","journal-title":"J Hepatol"},{"key":"4733_CR25","doi-asserted-by":"publisher","unstructured":"Marrone G, Maeso-D\u00edaz R, Garc\u00eda-Cardena G, Abraldes JG, Garc\u00eda-Pag\u00e1n JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64:1434\u201343. https:\/\/doi.org\/10.1136\/gutjnl-2014-308338.","DOI":"10.1136\/gutjnl-2014-308338"},{"key":"4733_CR26","doi-asserted-by":"publisher","unstructured":"Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut. 2020;0:1\u201310. https:\/\/doi.org\/10.1136\/gutjnl-2019-318237.","DOI":"10.1136\/gutjnl-2019-318237"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04733-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:37:16Z","timestamp":1775565436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04733-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4733"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04733-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Hospital Clinic de Barcelona approved the experimental protocol (HCB\/2018\/0028). The studies were conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DL and AZ are Gilead Sciences employees. Other authors, nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}